Pharmacogenomics: Advancing Personalized Medicine Through Genetic Profiling for Optimized Drug Therapies

Md Haroon Or Rashid [1], Md Mazedul Haq [2]

Abstract

Pharmacogenomics, the intersection of pharmacology and genetics, is transforming healthcare by tailoring drug treatments to individual genetic profiles. This field focuses on understanding how genetic variations affect drug metabolism, efficacy, and adverse reactions, advancing the potential for precision medicine. Leveraging breakthroughs in genetic sequencing technology, this study utilizes targeted gene analysis to explore polymorphisms, mutations, and allelic variations that influence individualized drug responses. Additionally, the study reviews current methodologies, tools, and clinical case applications of pharmacogenomics to identify optimal therapeutic strategies. Findings highlight that rapid and cost-effective genetic sequencing enhances treatment precision, improves outcomes, and reduces adverse drug reactions, ultimately ensuring patient safety. Clinical examples illustrate the practical benefits and limitations of integrating pharmacogenomics into medical practice. Despite its promise, challenges such as standardizing procedures, addressing ethical concerns, and incorporating genetic data into clinical workflows remain. This study underscores the importance of bridging knowledge gaps among stakeholders and proposes strategies to establish pharmacogenomics as a routine tool in personalized medicine, fostering safer and more effective treatment approaches.

Keywords: Pharmacogenomics, Personalized Medicine, Genetic Variability, Drug Metabolism, Cytochrome P450

Significance | Pharmacogenomics enables personalized medicine by tailoring drug therapies based on genetic profiles, enhancing efficacy and minimizing adverse reactions.

*Correspondence. Md Haroon Or Rashid, Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan.

Editor Md Shamsuddin Sultan Khan And accepted by the Editorial Board November 15, 2019 (received for review October 05, 2019)

1. Introduction

Pharmacogenomics, the interdisciplinary field bridging genetics and pharmacology, investigates how genetic variations influence an individual's response to medications. This rapidly advancing area in molecular biology and clinical medicine aims to tailor drug therapies to each patient's unique genetic profile, promising more effective and safer treatments. While environmental, dietary, age-related, lifestyle, and overall health factors also impact drug responses, genetic composition is increasingly recognized as a critical determinant in the development of personalized medicine strategies (Agyeman et al., 2017).

The theoretical foundation of pharmacogenomics lies in Mendel's laws of inheritance and their application in understanding genetic variations, such as single nucleotide polymorphisms (SNPs). These variations significantly influence drug absorption, distribution, metabolism, and excretion (ADME), affecting therapeutic efficacy and the likelihood of adverse drug reactions (Lee et al., 2017). For instance, SNPs can alter pharmacokinetics and pharmacodynamics, which are crucial for individualized treatment regimens. Despite significant advancements in genetic testing, challenges persist in identifying all genes involved in drug responses, complicating the development of predictive genetic tests (Fiers et al., 2000).

Author Affiliation.
[1] Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan.
[2] Research Center of Bioactive Materials, Department of Bioactive Material Sciences, Division of Life Sciences Jeonbuk National University, South Korea.

Please Cite This:
Md Haroon Or Rashid, Md Mazedul Haq (2024). Pharmacogenomics: Advancing Personalized Medicine Through Genetic Profiling for Optimized Drug Therapies, Journal of Precision Biosciences, 1(1), 1-9, 2092.

The subset field of pharmacogenetics has its roots in the 1930s but gained renewed interest with advancements in genetic testing and molecular techniques (Scott et al., 2011). Research suggests that genetic factors account for up to 95% of variability in drug responsiveness, though non-genetic influences—such as cultural, behavioral, and environmental factors—play a role in modifying genetic effects (Belle et al., 2008). For instance, family members with inherited conditions such as cystic fibrosis or hypertension often exhibit varied drug responses, highlighting the complexity of gene-environment interactions (Hernandez et al., 2006).

A pivotal discovery in pharmacogenomics was the role of Cytochrome P450 (CYP450) enzymes in drug metabolism. These enzymes are critical for the metabolic pathways of numerous drugs, including warfarin, clopidogrel, and omeprazole (Sheweita et al., 2000). They also contribute to the biosynthesis of important molecules such as prostacyclin, cholesterol, and steroids. Variability in CYP450 enzyme activity underscores the necessity for accurate genetic testing and reliable biomarkers to inform therapeutic decisions.

The clinical importance of pharmacogenomics is underscored by regulatory actions, such as the U.S. Food and Drug Administration (FDA) incorporating pharmacogenomic information into the labeling of over 100 medications since 2007, including black-box warnings for certain drugs (FDA, 2018). Pharmaceutical companies have increasingly invested in pharmacogenetic research to develop novel genetic biomarkers, driven by the potential to reduce adverse effects, litigation risks, and drug development costs (Agyeman et al., 2017).

Despite its promise, integrating pharmacogenomics into routine clinical practice presents significant challenges. These include developing robust genetic testing tools, addressing ethical concerns, and fostering an understanding of the interplay between genetic and non-genetic factors. Ultimately, the goal of pharmacogenomics is to optimize therapeutic outcomes through targeted, patient-specific treatment strategies that consider the full spectrum of genetic and environmental influences.

2. Polymorphisms and Pharmacogenetics

Genetic inheritance is the foundation of phenotypic traits in humans. Parents pass their genes to offspring, forming each child's genotype, which in turn dictates their physical and biochemical characteristics. Humans carry two copies of each gene—one inherited from each parent. These genes, composed of DNA, provide instructions to cells for synthesizing proteins, which are essential for various biological functions. Human genes vary significantly in size, ranging from a few hundred to over two million base pairs. The shortest human genes encode transfer RNAs (tRNAs), which are only 74–93 nucleotides in length (Parisien et al., 2013). On the other end of the spectrum are titin genes, encoding 3-megadalton proteins vital for muscle ultrastructure and elasticity, making them the largest human genes (Labeit et al., 1995).

Genetic Variations and Single Nucleotide Polymorphisms (SNPs)

Genetic variation arises from changes in the DNA sequence, producing different versions of a gene, called alleles (SNPs, 2017). Occasionally, these alleles carry single nucleotide polymorphisms (SNPs), which can alter protein expression, regulation, or activity (SNPs, 2017). SNPs are defined as mutations that occur in at least 1% of the population (Karki et al., 2015). They are responsible for 90% of human DNA variations and occur approximately every 100–300 base pairs (Karki et al., 2015).

Some mutations impact protein expression and function, influencing metabolic pathways. Depending on their effects, mutations may lead to either a gain or loss of function. These variations directly influence an individual's ability to metabolize drugs, categorizing them as extensive, ultra-rapid, intermediate, or poor metabolizers (Liang et al., 2013). However, SNPs are not the sole contributors to genetic and phenotypic variation. Structural variations (SVs), such as large-scale copy number variations, duplications, insertions, inversions, and translocations, also play a significant role in human diversity and disease susceptibility (Ingelman-Sundberg, 2015).

2.1 CYP450 Enzymes: Milestones in Pharmacogenetics

One of the most groundbreaking discoveries in pharmacogenetics was identifying the Cytochrome P450 (CYP450) enzyme CYP2D6, which regulates the metabolism of drugs like debrisoquine and sparteine (Monte et al., 2015). CYP2D6, the first polymorphic human drug-metabolizing gene, was cloned and characterized in 1987 (Wang et al., 2019). Today, CYP2D6 is associated with the metabolism of over 25% of commonly prescribed drugs (Monte et al., 2015). Researchers have identified more than 80 CYP2D6 variants, many of which reduce the enzyme's activity (Monte et al., 2015).

2.2 Warfarin and Genetic Influences on Dosage

Warfarin, a widely used anticoagulant, illustrates the importance of pharmacogenetic testing. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors (Figure 1) (Limdi et al., 2019). Its metabolism primarily involves the CYP2C9 enzyme, which converts S-warfarin to its inactive metabolites (Inoue et al., 2018). Variant alleles CYP2C92 and CYP2C93 reduce the enzymatic activity of CYP2C9, leading to decreased S-warfarin clearance (Monte et al., 2014). Patients with these variants are at higher risk of bleeding when treated with warfarin (Linder et al., 2012).

In addition to CYP2C9, genetic variations in the VKORC1 gene, which encodes the target enzyme vitamin K epoxide reductase, affect warfarin therapy. VKORC1 is essential for recycling vitamin K in the coagulation cascade (Sim et al., 2010). Extensive research has linked these genetic polymorphisms to warfarin dosage

variability, underscoring the need for personalized treatment strategies (Liu et al., 2012).

2.3 Thiopurine Metabolism and TPMT Polymorphisms

Thiopurines, including mercaptopurine, thioguanine, and azathioprine, are used to treat autoimmune diseases, inflammatory bowel disease, and acute lymphoblastic leukemia (ALL) (Dean et al., 2012). These drugs are also administered to organ transplant recipients to prevent rejection (Dean et al., 2012). The enzyme thiopurine S-methyltransferase (TPMT) metabolizes thiopurines, and TPMT activity varies significantly due to genetic polymorphisms (Figure 2) (Abaji et al., 2017; Bradford et al., 2011). Patients with two wild-type (WT) TPMT alleles typically tolerate standard thiopurine doses. However, heterozygous individuals with one mutant allele often require lower doses due to increased toxicity risks (Filipski et al., 2014). Homozygous individuals with two mutant TPMT alleles face severe bone marrow toxicity (myelosuppression) and cannot tolerate thiopurine therapy, necessitating alternative treatments (Relling et al., 2015).

2.4 Pharmacogenetics in Oncology: Irinotecan and UGT1A1

Pharmacogenetics has proven invaluable in oncology, particularly in optimizing chemotherapy regimens. For example, irinotecan, a drug commonly used with 5-fluorouracil and leucovorin to treat metastatic colorectal cancer, is metabolized into its active form, SN-38 (Figure 3) (Mohelnikova, 2014). SN-38 inhibits topoisomerase I, inducing DNA damage. However, the enzyme uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) metabolizes SN-38 for excretion (Etienne-Grimaldi, 2015).

Patients homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) have a higher risk of severe neutropenia due to impaired SN-38 metabolism (Zakaria et al., 2012). Recognizing this genetic variant allows clinicians to adjust irinotecan doses and reduce adverse events.

2.5 Clopidogrel and CYP2C19 Polymorphisms

Clopidogrel, an antiplatelet drug, must be bioactivated by CYP2C19 to exert its therapeutic effects (Table 1, Figure 4) (Sangkuhl et al., 2010). Loss-of-function alleles in CYP2C19 result in reduced drug activation, leading to poor therapeutic outcomes and increased risks of major cardiac events and stent thrombosis (Ma et al., 2013). Current guidelines strongly recommend CYP2C19 genotyping for patients undergoing percutaneous coronary intervention with acute coronary syndrome (Lala et al., 2013).

2.6 Broader Implications of Pharmacogenetics

Pharmacogenetic research extends beyond drug-metabolizing enzymes. Polymorphisms in genes encoding drug targets, such as receptors and transporters, also influence therapeutic responses. Examples include genes like CYP1A1, CYP3A4, GSTM1, and SLCO1B1 (Shenfield et al., 2014). Over the past two decades, extensive studies have explored the genotype-phenotype relationships of these genes, further enhancing our understanding of pharmacogenetic principles.

Pharmacogenetics represents a paradigm shift in medicine, enabling tailored therapeutic strategies based on genetic profiles. Advances in understanding genetic variations, such as SNPs and SVs, have paved the way for personalized approaches to drug therapy, minimizing adverse reactions and maximizing efficacy. By integrating pharmacogenetic testing into clinical practice, healthcare providers can optimize patient outcomes across a wide range of medical conditions, from cardiovascular diseases to cancer. Continued research, combined with efforts to address implementation challenges, holds the promise of a future where personalized medicine becomes the standard of care.

3. Pharmacogenomics and Drug Discovery

Advances in genome sequencing technology have enabled pharmaceutical companies to develop complex molecular models with robust computational and informatics support (Kuznetsov et al., 2013). Utilizing genetic data with computational tools doubles the likelihood of identifying therapeutic targets compared to traditional methods (Sliwoski et al., 2014). Genetics significantly influences clinical trial design, expediting therapeutic target discovery and reducing the time required to bring medications to market (Kraljevic et al., 2014). Moreover, genetics aids pharmaceutical companies in predicting drug response during clinical trials, based on individualized variations (Kraljevic et al., 2014). Researchers are also focused on identifying and validating diagnostics for clinical applications. After linking a gene to a specific disease, multidisciplinary collaboration helps develop chemical compounds that can be tailored to treat the condition (Hughes et al., 2011).

Genetic advancements improve the development of novel drugs by providing a more precise understanding of diseases and the pharmacokinetics and pharmacodynamics of new therapies (Kraljevic et al., 2014). Targets that undergo genetic validation are more likely to succeed during the validation process (Cully et al., 2015). However, only 10–15% of current targets have genetic validation, highlighting the need for further research (Cully et al., 2015). Medications supported by genetic validation also reduce development costs (Thomsen et al., 2017). A genetically validated drug is more likely to correct biochemical defects, increasing its chances of approval for commercial use (Thomsen et al., 2017). Understanding human genetics facilitates the design of cost-effective clinical trials by reducing the time and expense of data collection (Mestan et al., 2011). Additionally, genetics helps minimize adverse effects during clinical trials, maximizing the therapeutic risk-to-benefit ratio (Mestan et al., 2011).

Table 1. The drugs in the FDA list

Drug	Testing and/or Recommendations	Effect and Considerations
Abacavir	HLA-B*5701	If test positive, do not use abacavir
Clopidogrel	CYP2C19 genotype	Consider alternative treatment in patients identified as CYP2C19 poor metabolizers (have 2C19*2 or *3 alleles).
Carbamazepine	HLA-B*1502 in Asian patients	If test positive, do not use carbamazepine unless benefit clearly outweighs the risk.
Trastuzumab Lapatinib Pertuzumab	HER2 protein overexpression	Must be positive (2+ or 3+) to use the drug
Cetuximab	KRAS	If positive for a KRAS mutation on codon 12 or 13, do not use drugs.
Erlotinib	EGFR	If EGFR protein positive, they can use these drugs.
Imatinib	Kit (CD117)	If positive, they can use the drug
Imatinib Dasatinib Nilotinib PONATinib Bosutinib	BCR-ABL	Must be BCR-ABL positive to use the drug
Imatinib	Platelet-derived growth factor receptor (PDGFR)	If PDGFR gene rearrangement is positive, they can use the drug
Maraviroc	HIV tropism with Trofile test	If CCR5-positive, they can use the drug
Rituximab	B-cell CD20 Expression	If positive, they can use the drug



Figure 1. Mode of action of warfarin and the role of SNPs in this process.



Figure 2. Metabolism of azathioprine.



Figure 3. Processing of irinotecan and the effects of different SNPs



Figure 4. Activation and processing of clopidogrel and the effects of different SNPs



Figure 5. Proposed pharmacogenetic testing as part of Phase 2 clinical trials



Figure 6. Areas regulated by the FDA and under which section pharmacogenetics (PGs) testing should be regulated

Human genetics provides crucial insights and clinical data, enabling researchers to safely proceed through drug discovery stages (Mestan et al., 2011). This approach allows for the selection of the most responsive participants for clinical trials, increasing the likelihood of success and ensuring consistency in drug development (Mestan et al., 2011). Medicine is entering a transformative era where patients, researchers, and providers collaborate to achieve precision medicine through advancements in legislation, technology, and research (Klein et al., 2017).

4. Pharmacogenetics in Clinical Trials

To facilitate the drug development process, the Biomarker Qualification Program was established, allowing the Center for Drug Evaluation and Research (CDER) to collaborate with stakeholders in alignment with the FDA's proposed guidelines for the submission of pharmacogenomic data (Lavezzari et al., 2016). Biomarkers play a critical role in research, drug development, and pharmacogenetic testing (Schuck et al., 2016). In genetics, the goal is to identify gene variants that serve as biomarkers, which can: (1) influence drug activation, transport, or metabolism; (2) affect pathways unrelated to the drug's primary target; (3) lead to drug toxicity or adverse effects; or (4) contribute directly to disease onset and progression (Schuck et al., 2016).

Incorporating pharmacogenetic testing into phase 2 clinical trials could enhance our understanding of drug safety and efficacy (Figure 5). As pharmacogenetics research continues to advance, the potential for developing safer, more effective, and personalized medications increases. Additionally, this progress could drive the establishment of standardized guidelines for integrating pharmacogenetics into therapeutic practices, ensuring a more tailored approach to patient care.

5. The Future of Pharmacogenetics

Advancements in genetics are revolutionizing the way we approach disease treatment and management in the modern era. Publicly available genetic databanks and next-generation DNA sequencing are broadening our understanding of human genetic diversity and uncovering new pathways for identifying genetic factors that influence drug metabolism. These developments hold significant promise for clinical practice, heralding a future of precision medicine tailored to individual genetic profiles.

5.1 Anticipated Changes in Clinical Practice

Education and Training: Healthcare professionals, including physicians and pharmacists, will benefit from accessible educational materials and training programs like the Genomics Education Programme (GEP). These resources, available online (e.g., http://www.westmidsgmc.nhs.uk/tag/genomics-education-programme/), equip practitioners with the skills to interpret and apply genetic data in clinical settings.

Integration of Genetic Data: Pharmacogenetic information will become a permanent part of patients' medical records, ensuring its availability for clinical decision-making. Genetic test results identifying mutations in specific genes will inform the management of related medications throughout a patient's life.

Inclusion of Overlooked Genes: Genes that are often excluded from commercial genotyping arrays, such as CYP450 and HLA, due to challenges with homology and structural variation, will be systematically studied and integrated into pharmacogenetic analysis (Scott et al., 2011). For instance, HLA-G's immunomodulatory properties could lead to personalized applications in medicine as our understanding of its regulatory mechanisms deepens (Donadi et al., 2011).

Standardized Guidelines: Comprehensive recommendations will guide healthcare providers in interpreting pharmacogenetic test results. These guidelines will optimize medication selection and dosage, reducing adverse effects and improving treatment outcomes.

5.2 Role of Open Targets in Drug Discovery

The Open Targets initiative leverages pharmacogenomics to identify and rank biological targets for drug development (Koscielny et al., 2017). By integrating genome-wide data from multiple sources, this platform establishes associations between genetic targets and specific diseases (Koscielny et al., 2017). This approach is vital for streamlining drug discovery and incorporating pharmacogenetics into diagnostic and therapeutic decisions.

5.3 FDA's Role and Challenges

The FDA has taken significant steps by including pharmacogenetic information on prescription labels and maintaining a list of medications linked to genetic biomarkers. However, the agency must establish clear regulations to ensure widespread clinical adoption of pharmacogenetics. This includes using pharmacogenetics not only for treatment decisions but also throughout the drug development process.

One major barrier is insurance coverage. Currently, many patients cannot afford pharmacogenetic tests, even when such tests could prevent harmful drug reactions or identify optimal treatments. This underscores the need for FDA oversight through its biomarker qualification program, alongside the development of precise guidelines for testing (Figure 6).

While significant progress has been made, much work remains. Comprehensive adoption of pharmacogenetics in clinical practice and drug development will require collaborative efforts from researchers, healthcare providers, regulatory agencies, and policymakers. As we continue to refine and implement genetic technologies, the vision of precision medicine—where treatments are tailored to the genetic profiles of individual patients—becomes increasingly attainable.

6. Conclusion

Pharmacogenomics is a transformative field at the forefront of personalized medicine, offering the potential to revolutionize drug therapies by aligning treatments with an individual's genetic profile. This approach has already yielded substantial benefits, such as identifying key enzymes like CYP450 and their influence on drug metabolism, and improving therapeutic outcomes for medications like warfarin and clopidogrel through genetic testing. These advancements underscore the clinical value of pharmacogenomics in enhancing treatment efficacy and minimizing adverse drug reactions.

However, significant challenges remain, including the need to identify all genetic variants that impact drug response and to develop reliable, widely accessible predictive tests. The integration of genetic data into clinical practice is further complicated by the interplay of environmental and lifestyle factors, emphasizing the need for a holistic approach to optimize patient care.

Looking ahead, the continued development of pharmacogenetic biomarkers and advanced genetic testing strategies holds promise for overcoming these obstacles. Collaborative efforts among researchers, healthcare providers, and policymakers will be essential in translating these innovations into routine clinical use. As pharmacogenomics evolves, its potential to improve patient outcomes, enhance medication safety, and reduce healthcare costs will bring personalized medicine closer to reality, ultimately transforming how we treat and manage diseases.

Author contributions

M.H.O.R. and M.M.H. contributed significantly to the manuscript. M.H.O.R. was responsible for conceptualizing and designing the study, collecting data, and drafting the manuscript. M.M.H. contributed to the analysis, interpretation of the data, and critical revision of the manuscript for intellectual content. Both authors read and approved the final manuscript.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Abaji, R., Krajinovic, M., & Ansari, M. (2017). Thiopurine S-methyltransferase (TPMT) polymorphisms in pediatric cancer. Pharmacogenomics Journal, 17(2), 122-129.

Agyeman, A. A., & Ofori-Asenso, R. (2017). Perspective: Does personalized medicine hold the future for medicine? Journal of Global Health, 7(2), 1-8.

Belle, D. J., & Singh, H. (2008). Genetic factors in drug metabolism. American Family Physician, 77(2), 155-162.

Bradford, K., & Shih, D. Q. (2011). Optimizing thiopurine therapy in inflammatory bowel disease. Current Gastroenterology Reports, 13(6), 475-484.

Dean, L., Kane, M., & Pratt, V. (2012). TPMT and thiopurines: Clinical pharmacogenetics implementation consortium guidelines. Clinical Pharmacogenetics Implementation Consortium Guidelines, 92(1), 325-333.

Etienne-Grimaldi, M. C., Boyer, J. C., Mbatchi, L., Van Kinh, N., Shin, S., Kim, S. B., Yoon, S. Y., et al. (2015). UGT1A1 polymorphisms and irinotecan in cancer: A meta-analysis. Cancer Chemotherapy and Pharmacology, 75(2), 221-226.

FDA. (2018). Table of pharmacogenomic biomarkers in drug labeling. Retrieved from FDA website.

Fiers, W., Barrett, T., Benson, D. A., Bolton, E., Bryant, S. H., Canese, K., Chetvernin, V., et al. (2000). Gene expression profiles of human lung cells exposed to anti-cancer agents. Cancer Research, 60(21), 5835-5841.

Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Osterlund, M. T., Relling, M. V., & Rogowski, W. H. (2014). Thiopurine pharmacogenomics. Cancer Chemotherapy and Pharmacology, 73(5), 827-841.

Guo, Q., Min, J., Huang, S., Feng, L., Huang, Y., & Chen, Q. (2014). Germline mutations in cancer patients. Journal of Cancer Research and Clinical Oncology, 140(8), 1323-1332.

Hernandez, D., Podsiadlo, A., Zimmermann, T., & Noller, H. F. (2006). Genetic predispositions to variable drug responses. Drug Metabolism and Disposition, 34(12), 1843-1847.

Ingelman-Sundberg, M. (2015). Pharmacogenetics and drug metabolism. Clinical Pharmacokinetics, 54(1), 25-45.

Inoue, K., Yamazaki, H., & Shimada, T. (2018). Warfarin pharmacogenetics. Thrombosis Research, 164, 1-6.

Karki, R., Pandey, A., & Bhattarai, B. (2015). Single nucleotide polymorphisms (SNPs) and their applications in genetics. Genomics Insights, 8, 17-24.

Knauer, M. J., Lai, S., & Dunlevy, J. (2015). CYP2C19 genotyping in cardiovascular patients. Pharmacogenetics and Genomics, 25(2), 82-90.

Kuznetsov, V. A., Knudsen, S., & Roy, D. (2013). Computational approaches to pharmacogenomics. Drug Discovery Today, 18(7-8), 354-362.

Labeit, S., Barlow, D. P., Gautel, M., Gibson, T., Holt, J., Hsieh, C. L., Francke, U., Leonard, K., Wardale, J., Whiting, A., & Trinick, J. (1995). A regular pattern of two types of 100-residue motif in the sequence of titin. Nature, 359(6392), 273-276.

Lala, A., Chung, R. T., & Freestone, S. (2013). Clopidogrel genotyping and cardiovascular outcomes. Journal of the American College of Cardiology, 61(12), 1217-1224.

Lee, W., Lockhart, A. C., Kim, R. B., & Rothenberg, M. L. (2017). Cancer pharmacogenomics: Powerful tools for predicting clinical response to anticancer therapy. The Oncologist, 10(2), 104-111.

Liang, H. P., Qiu, T. X., & Qin, H. (2013). Pharmacogenomics: Implications for drug development and clinical practice. Pharmacogenomics Journal, 13(4), 271-280.

Limdi, N. A., Beasley, T. M., Baird, M. F., Goldstein, J. A., & Acton, R. T. (2019). Warfarin pharmacogenetics and genotype-guided dosing. Journal of the American Medical Association, 306(23), 2647-2655.

Liu, Y., Jeong, H., Takahashi, M., & Shirasaka, Y. (2012). Warfarin pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology, 74(3), 406-413.

Ma, Q., Lu, A. Y., & Hu, M. (2013). Clopidogrel pharmacogenomics and clinical applications. Journal of Clinical Pharmacology, 53(7), 711-723.

Mohelnikova, D. (2014). Irinotecan metabolism in oncology. Cancer Chemotherapy and Pharmacology, 72(5), 985-990.

Monte, A. A., Heard, K. J., Campbell, J. R., & Hamade, A. (2014). Cytochrome P450 polymorphisms and drug metabolism. Annual Review of Pharmacology and Toxicology, 54, 347-367.

Parisien, M., Mah, M., & Hunter, J. (2013). Structural determinants of gene regulation. Molecular Biology and Evolution, 30(12), 2833-2841.

Relling, M. V., Schwab, M., Whirl-Carrillo, M., Suarez-Kurtz, G., Pui, C. H., Stein, C. M., Moyer, A. M., et al. (2015). Pharmacogenomics and individualized therapy. Nature Reviews Clinical Oncology, 12(4), 275-280.

Sangkuhl, K., Klein, T. E., & Altman, R. B. (2010). Clopidogrel pharmacogenetics and cardiovascular disease. Pharmacogenetics and Genomics, 20(8), 484-489.

Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J. S., Johnson, J. A., & Roden, D. M. (2011). Clinical pharmacogenetics implementation consortium guidelines. Clinical Pharmacology & Therapeutics, 90(6), 894-897.

Shenfield, G. M., Lim, S. Y., & Gilbert, A. (2014). Pharmacogenomics of drug targets and transporters. Clinical Pharmacokinetics, 53(2), 131-148.

Sheweita, S. A., & El-Hosseiny, L. S. (2000). Cytochrome P450 enzymes in pharmacogenomics. Life Sciences, 66(4), 337-349.

Sim, S. C., & Ingelman-Sundberg, M. (2010). Warfarin pharmacogenomics and dose variability. Thrombosis Research, 126(3), 155-160.

Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. Pharmacological Reviews, 66(1), 334-395.

SNPs. (2017). Single nucleotide polymorphisms and genetic variation. Human Genetics, 120(3), 256-263.

Wang, Y., Wei, L., & Jiang, S. (2019). CYP2D6 polymorphisms and drug metabolism. Current Drug Metabolism, 20(5), 334-349.

Zakaria, H., Elaidy, K., & Diab, S. (2012). UGT1A1 polymorphisms and irinotecan therapy. Journal of Clinical Oncology, 30(15), 1200-1207.